By proceeding, you agree to our Terms of Use and Privacy Policy.
There aren’t many targets like BCMA - well validated, preferentially expressed by mature B lymphocytes and specific to multiple myeloma – meaning that novel drugs against BCMA continue to emerge.
Gain insights on exploring and differentiating the next-generation drug modalities targeting BCMA and sharing toxicology data to optimize drug potency.
Discover strategies for investigating multiple myeloma biology and quantify BCMA using optimized preclinical models and translation of preclinical assets.
Learn and network with industry experts like Brandon Kremer, Chetasi Talati, David DiLillo, Suzette Girgis, Marc-Steffen Raab, Mike Damore and others.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.